Anzeige
Mehr »
Mittwoch, 13.05.2026 - Börsentäglich über 12.000 News
Bahnbrechende KI-Lösung "Ohne Nadelstiche" als Ersatz für herkömmliche Bluttests "unlocked"?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
302 Leser
Artikel bewerten:
(1)

Optimus HealthCare Services, Inc: Clinical Research Alliance Announces Clinical Trial Partnership with Vantage Health

Combining decades of expertise in delivering healthcare services and expanding patient access to clinical trials.

NEW YORK, NY / ACCESSWIRE / November 10, 2022 / Clinical Research Alliance (CRA), a division of Optimus Healthcare Services, Inc. (OTC Pink:OHCS), announced a new strategic partnership with Vantage Health, by which they will be offering clinical trials focused on improving cancer treatment modalities and increasing the quality of cancer screenings. Together, CRA and Vantage Health will be offering important clinical trials for cancer, including breast cancer and pancreatic cancer, for patients in the New York City area.

CRA is comprised of dedicated physicians and healthcare professionals that are committed to providing patients with the opportunity to participate in clinical trials testing potential cancer treatments in their local communities. CRA has a community-oriented mindset and is focused on helping underserved communities and patient populations. CRA assists local physicians in providing high quality patient care and integrity of clinical services on the front line of disease. CRA has participated in close to 200 decentralized trials delivering access to thousands of patients.

"We're proud of the work we've accomplished with leaders in the industry to serve patients locally in clinical trials, and we are looking forward to partnering with Vantage Health in order to improve healthcare for New York City area patients and beyond" said John Sganga, President and CEO of CRA.

Vantage Health has long been committed to compassionate, comprehensive cancer care and individualized attention for every patient. "At Vantage Health, we pride ourselves in going the extra mile for our patients. With these new trials, we will be able to offer patients who have tried other, more conventional therapies another potential treatment option. We will also be able to work towards improving current screening methods, increasing the probability of early detection. This is a win-win for patients" said Summer Sharaf CEO of Vantage Health.

Vantage Health positions community physicians to provide local, individualized, and compassionate care to patients at nine locations in New York City. With decades of combined experience in radiation oncology, surgery, urology, and hematology, Vantage Health's team includes award-winning physicians who are widely respected as innovative leaders in their fields.

About Clinical Research Alliance

CRA enables access to clinical research-making it easier for patients and providers to participate and accelerating the development of new and innovative cancer treatments that impact patient lives. By providing state-of-the-art clinical research in a community setting, they also make clinical research more accessible to underserved populations that enable faster enrollment, better retention and a patient population that is representative of real-world populations.

LinkedIn: clinical-research-alliance | Instagram: @clinicalresearchalliance | Facebook: @ClinicalResearchAlliance | https://www.clinicalresearchalliance.org/

About Vantage Health

Vantage Health positions community physicians to provide local, individualized, and compassionate care to patients at fourteen (14) locations in New York City. With decades of combined experience in radiation oncology, surgery, urology, and hematology, Vantage Health's team includes award-winning physicians who are widely respected as innovative leaders in their fields. https://www.vantagehealth.com/

Caution Concerning Forward Looking Statements:

This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not a guarantee of future actions or performance. These forward-looking statements are based on information currently available to Optimus and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning Optimus's business are described in Periodic and Current Reports filed with the OTCIQ and the SEC. Optimus is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Cliff Saffron, Chief Financial Officer
csaffron@theoptimushealthcare.com
516-806-4201

SOURCE: Optimus HealthCare Services, Inc.

View source version on accesswire.com:
https://www.accesswire.com/724635/Clinical-Research-Alliance-Announces-Clinical-Trial-Partnership-with-Vantage-Health

© 2022 ACCESS Newswire
Vergessen Sie Gold, Silber und Öl: Nächste Megarallye startet!
Die Märkte feiern neue Rekorde – doch im Hintergrund braut sich eine Entwicklung zusammen, die alles verändern könnte. Die anhaltende Sperrung der Straße von Hormus sorgt laut IEA für eine der größten Energiekrisen aller Zeiten. Gleichzeitig schießen die Preise für Düngemittel und Agrarrohstoffe bereits nach oben.

Damit droht ein perfekter Sturm: steigende Energiepreise, explodierende Produktionskosten und ein möglicher Super-El-Nino, der weltweit Ernten gefährdet. Erste Auswirkungen sind längst sichtbar – Weizen, Soja und Kakao verteuern sich deutlich, während Lebensmittelpreise vor dem nächsten Sprung stehen könnten.

Für Anleger bedeutet das nicht nur Risiken, sondern enorme Chancen. Denn während klassische Märkte unter Druck geraten könnten, entsteht auf den Feldern und Plantagen der nächste große Rohstoffzyklus. Wer sich jetzt richtig positioniert, kann von einer Entwicklung profitieren, die weit über Öl und Metalle hinausgeht.

In unserem aktuellen Spezialreport stellen wir drei Aktien vor, die besonders aussichtsreich sind, um von diesem Trend zu profitieren – solide positioniert, strategisch relevant und mit erheblichem Aufwärtspotenzial.



Jetzt den kostenlosen Report sichern – bevor der Agrar-Boom voll durchschlägt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.